Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

56.96 +1.25 (+2.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Crispr Therapeutics Ag

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
26 27 Next >
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time
Wood is going all in on gene editing. 
Via The Motley Fool
3 Gene Editing Stocks to Generate Super-Charged Gains
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks. 
Via InvestorPlace
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
The company can begin a pivotal study of its treatment for cardiomyopathy. 
Via Investor's Business Daily
Cathie Wood-Led Ark Invest Sells Over $6.5M Worth Of Tesla Stock, What's Going On?
Via Benzinga
Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges
Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches... 
Via Benzinga
Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst
Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw 
Via Benzinga
Mixed Signals For CRISPR Therapeutics, Analyst Weighs Barriers, Potential Sales For Sickle Cell Therapy
Cantor Fitzgerald has downgraded CRISPR Therapeutics AG (NASDAQ: CRSP) to Neutral from Ov 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
Via Benzinga
This Cathie Wood Stock Is Set to Soar 100%, Says Wall Street
This Wood favorite is heading for a big moment. 
Via The Motley Fool
2 Growth Stocks That Could Double Your Money, According to Wall Street
Find out why investment bank analysts are pounding the table on these stocks. 
Via The Motley Fool
2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years
These two gene-editing stocks could be diamonds in the rough. 
Via The Motley Fool
Cathie Wood's Ark Invest Sells $9.8M Worth Of Tesla Shares — Second Day Of Selling EV Giant In A Row
Via Benzinga
Cathie Wood's Ark Invest Keeps On Cutting Tesla Holdings, Sells More Than $8M Worth Of EV Maker's Shares
Via Benzinga
Cathie Wood Is Buying CRISPR Therapeutics Ahead of This Big Event. Should You?
Wood has outperformed the market so far this year. 
Via The Motley Fool
Cathie Wood Goes Shopping For Stock of Jack Dorsey's Block — Ark Invest Bolsters Portfolio With Archer Aviation, CRISPR Shares
Via Benzinga
3 No-Brainer Growth Stocks to Buy in October
The time is right to invest in these great stocks. 
Via The Motley Fool
2 Growth Stocks That Can Rocket 98% to 108% Higher, According to Wall Street
The analysts who follow these stocks have some big expectations for the year ahead. 
Via The Motley Fool
Cathie Wood's Ark Invest Sells Over $25M Worth Of Tesla Shares Amid Boost In Price
Via Benzinga
Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich
Are you looking to invest in biotechnology breakthroughs? Here are three biotech stocks that could make early investors rich. 
Via InvestorPlace
Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?
The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome. 
Via The Motley Fool
2 Top Biotech Stocks to Buy in October
Growth catalysts lie ahead for both of these players. 
Via The Motley Fool
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics
The better of the pair should be able to beat Bluebird Bio. 
Via The Motley Fool
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
These companies are helping change medicine; they could make boatloads of money along the way. 
Via The Motley Fool
3 Cathie Wood Stocks Set to Explode Higher
Delve into the exciting world of Cathie Wood Stocks where potential meets performance, offering investors hefty long-term upside. 
Via InvestorPlace
Futurescape: Betting Big on These 3 Next-Gen Tech Stocks
These next-gen tech stocks that emphasize forward-thinking innovation are perfect for investors who seek big bets or massive gains. 
Via InvestorPlace
3 No-Brainer Growth Stocks to Buy in October
These three top mid-cap stocks could be poised for a long-tailed growth spurt. 
Via The Motley Fool
Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock
Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors. 
Via Benzinga
Why Editas Medicine Stock Is Soaring Today
Investors are cheering a big analyst upgrade for the gene-editing stock. 
Via The Motley Fool
If I Could Only Buy 3 Stocks in 2023, I'd Pick These
These stocks have what it takes to grow in leaps and bounds. 
Via The Motley Fool
Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment
The FDA is within three months of making a decision on the first-ever CRISPR-based drug. 
Via Investor's Business Daily
Exposures Product Safety
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.